268 related articles for article (PubMed ID: 38165473)
21. Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice.
Olsen SR
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S306-10. PubMed ID: 16507399
[TBL] [Abstract][Full Text] [Related]
22. Cyclooxygenase-2 as a target for anticancer drug development.
Méric JB; Rottey S; Olaussen K; Soria JC; Khayat D; Rixe O; Spano JP
Crit Rev Oncol Hematol; 2006 Jul; 59(1):51-64. PubMed ID: 16531064
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Cusimano A; Foderà D; D'Alessandro N; Lampiasi N; Azzolina A; Montalto G; Cervello M
Cancer Biol Ther; 2007 Sep; 6(9):1461-8. PubMed ID: 18424914
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2: a therapeutic target for prostate cancer.
Pruthi RS; Wallen EM
Clin Genitourin Cancer; 2005 Dec; 4(3):203-11. PubMed ID: 16425990
[TBL] [Abstract][Full Text] [Related]
25. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
26. Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors.
Wang R; Guo L; Wang P; Yang W; Lu Y; Huang Z; Tang C
Curr Pharm Des; 2013; 19(1):115-25. PubMed ID: 22950494
[TBL] [Abstract][Full Text] [Related]
27. COX-2 as a target for cancer chemotherapy.
Ghosh N; Chaki R; Mandal V; Mandal SC
Pharmacol Rep; 2010; 62(2):233-44. PubMed ID: 20508278
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of 11β-Hydroxysteroid Dehydrogenase Type II Suppresses Lung Carcinogenesis by Blocking Tumor COX-2 Expression as Well as the ERK and mTOR Signaling Pathways.
Chang J; Xue M; Yang S; Yao B; Zhang B; Chen X; Pozzi A; Zhang MZ
PLoS One; 2015; 10(5):e0127030. PubMed ID: 26011146
[TBL] [Abstract][Full Text] [Related]
29. Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.
Liu H; Deng R; Zhu CW; Han HK; Zong GF; Ren L; Cheng P; Wei ZH; Zhao Y; Yu SY; Lu Y
Acta Pharmacol Sin; 2024 Jan; 45(1):193-208. PubMed ID: 37749237
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase in the treatment of glioma: its complex role in signal transduction.
New P
Cancer Control; 2004; 11(3):152-64. PubMed ID: 15153839
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Rahman M; Selvarajan K; Hasan MR; Chan AP; Jin C; Kim J; Chan SK; Le ND; Kim YB; Tai IT
Neoplasia; 2012 Jul; 14(7):624-33. PubMed ID: 22904679
[TBL] [Abstract][Full Text] [Related]
32. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
[TBL] [Abstract][Full Text] [Related]
33. COX-2 inhibition and lung cancer.
Sandler AB; Dubinett SM
Semin Oncol; 2004 Apr; 31(2 Suppl 7):45-52. PubMed ID: 15179623
[TBL] [Abstract][Full Text] [Related]
34. COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy.
Goossens L; Pommery N; Hénichart JP
Curr Top Med Chem; 2007; 7(3):283-96. PubMed ID: 17305571
[TBL] [Abstract][Full Text] [Related]
35. Influencing COX-2 Activity by COX Related Pathways in Inflammation and Cancer.
Yu T; Lao X; Zheng H
Mini Rev Med Chem; 2016; 16(15):1230-1243. PubMed ID: 27145850
[TBL] [Abstract][Full Text] [Related]
36. Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer.
Alqahtani AM; Chidambaram K; Pino-Figueroa A; Chandrasekaran B; Dhanaraj P; Venkatesan K
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1916-1927. PubMed ID: 33660801
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
Ganesh R; Marks DJ; Sales K; Winslet MC; Seifalian AM
World J Surg Oncol; 2012 Sep; 10():200. PubMed ID: 23013454
[TBL] [Abstract][Full Text] [Related]
38. [Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
Réti A
Magy Onkol; 2010 Dec; 54(4):377-81. PubMed ID: 21163769
[TBL] [Abstract][Full Text] [Related]
39. COX-2 inhibitors act as radiosensitizer in tumor treatment.
Sminia P; Kuipers G; Geldof A; Lafleur V; Slotman B
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S272-5. PubMed ID: 16507391
[TBL] [Abstract][Full Text] [Related]
40. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
